Indolent lymphoma: the pathologist's viewpoint.

[The fatal traffic accident from the pathologist's viewpoint].

Eye Lymphoma: a Case Report

Non Hodgkin Lymphomas (NHL) are nodal or extra nodal monoclonal infiltrations by malignant lymphoid cells (B Lymphocytes in 80% of cases), which are distinguished as indolent or aggressive forms. According to the heterogeneity of lymphoid cells and their ubiquitous anatomical distribution, these disorders can develop in any organ and have very heterogeneous clinical expressions, but they are...

Hodgkin's lymphoma: the pathologist's viewpoint.

Despite its well known histological and clinical features, Hodgkin's lymphoma (HL) has recently been the object of intense research activity, leading to a better understanding of its phenotype, molecular characteristics, histogenesis, and possible mechanisms of lymphomagenesis. There is complete consensus on the B cell derivation of the tumour in most cases, and on the relevance of Epstein-Barr...

Prognostic Assessment in Patients with Indolent B-Cell Lymphomas

Follicular lymphoma (FL) is an indolent lymphoma with long median survival. Many studies have been performed to build up prognostic scores potentially useful to identify patients with poorer outcome. In 2004, an international consortium coordinated by the International Follicular Lymphoma Prognostic Factor project was established and a new prognostic study was launched (FLIPI2) using progressio...

Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis

BACKGROUND Bortezomib is recently studied as a novel agent in indolent lymphoma. The optimal schedule of bortezomib used in indolent lymphoma is still uncertain. METHODS We did a systematic review and meta-analysis of the clinical trials comparing the efficacy and toxicity of the weekly and biweekly schedules of bortezomib in patients with indolent lymphoma. We searched Pubmed, Cochrane Libra...